BR9713256A - Forma de dosagem de bisacodil com revestimento polimérico múltiplo entérico para liberação colÈnica - Google Patents

Forma de dosagem de bisacodil com revestimento polimérico múltiplo entérico para liberação colÈnica

Info

Publication number
BR9713256A
BR9713256A BR9713256-0A BR9713256A BR9713256A BR 9713256 A BR9713256 A BR 9713256A BR 9713256 A BR9713256 A BR 9713256A BR 9713256 A BR9713256 A BR 9713256A
Authority
BR
Brazil
Prior art keywords
approximately
coating layer
enteric polymer
dosage form
colon
Prior art date
Application number
BR9713256-0A
Other languages
English (en)
Inventor
Gary Robert Kelm
Koji Kondo
Akio Nakajima
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9713256A publication Critical patent/BR9713256A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>"FORMA DE DOSAGEM DE BISACODIL COM MúLTIPLOS REVESTIMENTOS DE POLìMERO ENTéRICO PARA DISTRIBUIçãO COLÈNICA"<D>. A presente invenção refere-se a uma composição farmacêutica em uma forma de dosagem unitária, para administração peroral em um ser humano ou animal inferior com um trato gastrintestinal compreendendo um intestino delgado e um cólon com um lúmen através do mesmo, com uma entrada do intestino delgado para o cólon, que compreende: a) uma quantidade segura e eficaz de bisacodil de rápida dissolução, incorporado em uma pastilha comprimida, biconvexa, com um diâmetro máximo de aproximadamente 4 mm a aproximadamente 10 mm; b) um revestimento alizador não dependente de pH aplicado à pastilha, para obter uma superfície de pastilha lisa, livre de arestas e curvas agudas; e c) um material de revestimento de polímero entérico, que compreende pelo menos uma camada de revestimento interna e apenas uma camada de revestimento externa, em que o bisacodil de rápida dissolução é liberado em um ponto proximo à entrada ou dentro do cólon; cada qual da(s) camada(s) de revestimento interna é um polímero entérico que começa a dissolver-se em um meio aquoso, a um pH entre aproximadamente 5 a aproximadamente 6,3; e a camada de revestimento externa é um polímero entérico que começa a dissolver-se em um meio aquoso, a um pH entre aproximadamente 6,8 a aproximadamente 7,2.
BR9713256-0A 1996-10-11 1997-10-10 Forma de dosagem de bisacodil com revestimento polimérico múltiplo entérico para liberação colÈnica BR9713256A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/728,945 US5843479A (en) 1993-02-26 1996-10-11 Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
PCT/US1997/018556 WO1998016229A1 (en) 1996-10-11 1997-10-10 Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery

Publications (1)

Publication Number Publication Date
BR9713256A true BR9713256A (pt) 2001-06-19

Family

ID=24928908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713256-0A BR9713256A (pt) 1996-10-11 1997-10-10 Forma de dosagem de bisacodil com revestimento polimérico múltiplo entérico para liberação colÈnica

Country Status (7)

Country Link
US (1) US5843479A (pt)
EP (1) EP0932404A1 (pt)
JP (1) JP4216912B2 (pt)
CN (1) CN1237908A (pt)
BR (1) BR9713256A (pt)
CA (1) CA2268868C (pt)
WO (1) WO1998016229A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6028190A (en) 1994-02-01 2000-02-22 The Regents Of The University Of California Probes labeled with energy transfer coupled dyes
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
EP0903428A3 (de) * 1997-09-03 2000-07-19 Leybold Systems GmbH Einrichtung und Verfahren für die Bestimmung von Durchmessern eines Kristalls
US6100245A (en) * 1999-09-07 2000-08-08 Mcneil-Ppc, Inc. Use of simethicone to treat ulcerative colitis
CN1288730A (zh) * 1999-09-07 2001-03-28 麦克内尔-Ppc股份有限公司 轻泻组合物
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
BRPI0210096B1 (pt) * 2001-05-30 2015-06-30 Euro Celtique Sa Composição farmacêutica compreendendo bissacodil e poloxâmero, processo para a preparação de composição farmacêutica na forma de cápsula cheia e uso de poloxâmero e bissacodil
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
JPWO2004024138A1 (ja) * 2002-09-10 2006-01-05 大正製薬株式会社 ジオクチルソジウムスルホサクシネート配合固形製剤
JP4821607B2 (ja) * 2004-03-10 2011-11-24 大正製薬株式会社 水難溶性薬物配合固形製剤
US20060093560A1 (en) * 2004-10-29 2006-05-04 Jen-Chi Chen Immediate release film coating
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
JP2009541337A (ja) * 2006-06-19 2009-11-26 マクニール−ピーピーシー・インコーポレーテツド 活性成分を含有する腸溶性の被覆された粒子
AU2008253583A1 (en) * 2007-05-17 2008-11-27 David Lubowski Combination laxative compositions comprising a colonic stimulant and a bulking laxative
AR071706A1 (es) * 2008-05-15 2010-07-07 Otsuka Pharma Co Ltd Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion.
US8663671B2 (en) 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
CN109172816A (zh) 2012-03-29 2019-01-11 塞拉拜姆有限责任公司 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂
NO2659881T3 (pt) * 2012-04-30 2018-04-28
US8313774B1 (en) 2012-06-26 2012-11-20 Magnifica Inc. Oral solid composition
ES2801801T3 (es) * 2012-09-21 2021-01-13 Ferring Bv Composición farmacéutica
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP3031456A4 (en) * 2013-08-06 2016-12-28 Tasly Pharmaceutical Group Co USE OF ANDROGRAPHOLIDE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY ENDURANCE, ENTERAL ANDROGRAPHOLIDE MICROPELLET AND METHOD FOR THE MANUFACTURE THEREOF
JP6501923B2 (ja) * 2015-06-22 2019-04-17 シーティーシー バイオ インコーポレイテッド 腸管洗浄用の下剤組成物
JP7046323B2 (ja) * 2017-09-13 2022-04-04 アリメント工業株式会社 多層被覆製剤
CN113230224B (zh) * 2021-05-17 2022-04-22 药大制药有限公司 一种比沙可啶片剂及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2764590A (en) * 1952-03-17 1956-09-25 Thomae Gmbh Dr K Certain 4, 4'-disubstituted-diphenylpyridyl methanes and process
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
LU72439A1 (pt) * 1975-05-09 1977-02-09
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
JPS5799521A (en) * 1980-12-11 1982-06-21 Eisai Co Ltd Solid composition containing bisacodyl
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
JPS59193816A (ja) * 1983-04-19 1984-11-02 Morishita Jintan Kk 腸溶性軟カプセルの製造法
FR2556965B1 (fr) * 1983-12-21 1986-08-22 Rhone Poulenc Sante Nouvelle forme galenique du ketoprofene a liberation controlee
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS61221117A (ja) * 1985-03-26 1986-10-01 Fujisawa Pharmaceut Co Ltd 腸溶性硬カプセル剤
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4822629A (en) * 1986-12-12 1989-04-18 Norwich Eaton Pharmaceuticals, Inc. Azumolene dosage form
US4816259A (en) * 1987-02-12 1989-03-28 Chase Chemical Company, L.P. Process for coating gelatin capsules
JPS63258815A (ja) * 1987-04-16 1988-10-26 Kiyuushin Seiyaku Kk ビサコジル含有固形組成物
JP2782691B2 (ja) * 1987-09-29 1998-08-06 ワーナー−ランバート・コンパニー 腸溶製剤の安定化
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
JPH089536B2 (ja) * 1987-10-30 1996-01-31 日清製粉株式会社 腸溶性カプセルの製造方法
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
JP2849929B2 (ja) * 1989-10-19 1999-01-27 チッソ株式会社 透湿性積層体
IL98087A (en) * 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
JPH064531B2 (ja) * 1990-06-04 1994-01-19 アイセロ化学株式会社 大腸崩壊性硬質カプセル
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
DE9015551U1 (pt) * 1990-11-14 1992-03-12 Roehm Gmbh, 6100 Darmstadt, De
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
DK0686034T3 (da) * 1993-02-26 2001-08-27 Procter & Gamble Bisacodyl-doseringsform
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
DE4314799C2 (de) * 1993-05-05 1995-04-13 Fein C & E Elektrowerkzeug

Also Published As

Publication number Publication date
CA2268868A1 (en) 1998-04-23
EP0932404A1 (en) 1999-08-04
CA2268868C (en) 2004-03-09
JPH10203983A (ja) 1998-08-04
WO1998016229A1 (en) 1998-04-23
US5843479A (en) 1998-12-01
JP4216912B2 (ja) 2009-01-28
CN1237908A (zh) 1999-12-08

Similar Documents

Publication Publication Date Title
BR9713256A (pt) Forma de dosagem de bisacodil com revestimento polimérico múltiplo entérico para liberação colÈnica
BR9712292A (pt) Forma de dosagem farmacêutica com revestimentos de polímero entérico m·ltiplo para entrega colónica
ATE251899T1 (de) Pharmazeutische dosierungsform zur freisetzung im colon
DE69619668T2 (de) Pharmazeutische dosisform mit mehrfacher darmlöslicher polymerbeschichtung zur wirkstoffabgabe im kolon
ES2198756T3 (es) Sistema de administracion de farmacos de liberacion total retardada en el tracto gastrointestinal.
BR0007454A (pt) Dispositivos e métodos de implante comtransferência de droga biocompatìvel deliberação controlada no sistema ocular
DE60237372D1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
ES2162874T3 (es) Composicion farmaceutica para hacer llegar medicamentos hasta el colon.
BR9807368A (pt) Comprimidos de oxacarvazepina revestidos com pelìcula
ID17428A (id) Sediaan farmasi da;lam bentuk kapsult bersalut yang dapat dilepas pada bagian bawah saluran pencernaan
ES2157253T3 (es) Forma de dosificacion de bisacodilo.
FI98343B (fi) Peroraalinen formulaatio
PT98374A (pt) Dispositivo osmotico para administracao sistemica de nicotina e processo nele baseado
CA2271569A1 (en) Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
BR9612800A (pt) Forma de dosagem farmacêutica para distribuição colÈnica.
BR9612801A (pt) Forma de dosagem farmacêutica com múltiplos revestimentos de polìmeros entéricos para o fornecimento colÈnico.
CA2271560A1 (en) Pharmaceutical dosage form for colonic delivery
NO992349L (no) Farmas°ytisk doseform for avlevering i tykktarmen
EP0375649A3 (en) Swelling-controlled oral delivery system for drugs
ES2112747B1 (es) Formulaciones farmaceuticas solidas orales para un carbonato basico de aluminio y magnesio con una disponibilidad palatabilidad mejorada.
CO4130184A1 (es) Forma de dosificacion de bisacodyl
IT8821437A0 (it) Procedimento per prolungare la permanenza nel tratto gastrointestinale di farmaci in formulazioni ad effetto prolungato e forme di dosaggio cosi&#39; ottenute.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US)

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1835 DE 07/03/2006.